For investors, it can be quite challenging to decide if the Fabtech Technologies IPO is a good investment or not. If you are unsure and still thinking about whether to apply or skip this IPO, don’t worry. In this article, we present the top key factors and a detailed review of the Fabtech Technologies IPO. This will help you analyze the strengths, risks, and financial details of the Fabtech Technologies IPO, making your investment decision better.
About Company
Fabtech Technologies Limited, Founded in 2018, is one of the growing biopharma engineering companies. Fabtech is involved in offering turnkey projects such as cleanroom facilities, modular systems, and custom engineering solutions. They operate in over 62 countries across the Middle East, Africa, Asia, Europe, Latin America, and North America, with presence in key markets like India, the USA, the UAE, Saudi Arabia, Egypt, Kenya, Nigeria, and South Africa.
The company is involved in offering end-to-end services for projects, including disease identification, planning, design, engineering, procurement, quality checks, logistics, and installation, serving customers worldwide. Moreover, the company also offers a wide range of equipment for purified water, pure steam, and water for injections, with flow rates from 500 LPH to 50,000 LPH. The company serves the Life sciences, food & beverage, IT, semiconductor, and aeronautics industries. The company includes 185 permanent employees as of July 31, 2025.
Strengths
- Fabtech Technologies is one of the leading turnkey providers offering integrated engineering solutions with complete services.
- It offers an asset-light, fully integrated business model.
- Strong in-house software technology capabilities.
- Fabtech Technologies comes with a diversified order book spread across regions, clients, and business segments.
Weaknesses
- The company’s current order book might not reflect the future results. The projects in the order book or upcoming projects may be delayed, changed, or canceled due to factors beyond our control, which can badly affect the business, reputation, profitability, and financial performance.
- They mainly depend on a few projects for most of their revenue. If any of these projects are canceled by customers, it can negatively impact the business, cash flow, and overall performance.
- Fabtech Technologies is engaged in offering high-quality equipment and engineering services to customers. If they fail to meet these standards, then it can lead to various losses like order cancellations, recalls, claims, or financial losses, which can harm the company’s reputation and business.
- Previously, the company has experienced negative cash flows, and may continue to do so in the future, which can badly impact the business, prospects, and financial condition.
Fabtech Technologies IPO Review
| Reviewer | Recommendation |
| IPO Watch | May Apply |
| Adroit Financial Services Private Limited | Apply |
| BP Equities (BP Wealth) | Apply |
| Capital Market | Neutral |
| Marwadi Shares and Finance Ltd | Apply |
| SBICAP Securities Limited | Neutral |
| SMIFS Limited | Apply |
| Stoxbox by BP Equities Pvt Ltd | Apply |
| Ventura Securities Limited | Apply |
Fabtech Technologies IPO Details
| IPO Open Date: | September 29, 2025 |
| IPO Close Date: | October 1, 2025 |
| Face Value: | ₹10 Per Equity Share |
| IPO Price Band: | ₹181 to ₹191 Per Share |
| Issue Size: | ₹230.35 Crores |
| Fresh Issue | ₹230.35 Crores |
| Registrar | Bigshare Services Pvt.Ltd.. |
| IPO Lead Managers | Unistone Capital Pvt.Ltd. |
| Basis of Allotment | October 3, 2025 |
| IPO Listing Date: | October 7, 2025 |
| Listing | BSE, NSE |
Financial Performance Trend Details
| Particulars | For the year ended March 31, 2025 | For the year ended March 31, 2024 | For the year ended March 31, 2023 |
| Revenue from Operations | ₹335.94 Cr | ₹230.39 Cr | ₹199.91 Cr |
| EBITDA | ₹47.28 Cr | ₹40.69 Cr | ₹34.86 Cr |
| EBITDA Margin (%) | 14.07% | 17.24% | 16.20% |
| Profit after Tax (PAT) | ₹46.45 Cr | ₹27.22 Cr | ₹21.73 Cr |
| Net Worth | ₹173.11 Cr | ₹131.88 Cr | ₹88.96 Cr |
| Total Borrowings | ₹54.62 Cr | ₹9.88 Cr | ₹34.29 Cr |
Key Performance Indicator
| KPI | Values |
| ROE | 30.46% |
| ROCE | 24.46% |
| Debt/Equity | 0.32 |
| RoNW | 26.83% |
| PAT Margin | 13.83% |
| EBITDA Margin | 14.07% |
| Price to Book Value | 3.57 |
Promoters & Track Records, if any
- Aasif Ahsan Khan, aged 57 years, is the Promoter of the Company. He holds 1,84,56,779 shares, representing 56.98% of pre-Issue paid-up capital in the company.
- Hemant Mohan Anavkar, aged 63 years, is the Promoter and Executive Director of the Company. He holds 38,08,761 shares, representing 11.76% of pre-issue paid-up capital in the company.
- Aarif Ahsan Khan, aged 54 years, is the Promoter of the Company. He holds 45,70,500 shares, representing 14.11% of pre-issue paid-up capital in the company.
- Manisha Hemant Anavkar, aged 56 years, is the Promoter of the Company. She holds 38,08,772 shares, representing 11.76% of pre-issue paid-up capital in the company.
Object of the IPO
- The proceeds raised from the fresh issue will be utilized towards the working capital requirement of the company.
- Some funds will be utilized towards expanding the business through acquisitions.
- Lastly, the remaining funds will be used for the company’s general corporate purposes.
Fabtech Technologies IPO – Should You Apply or Not?
Fabtech Technologies has demonstrated consistent revenue growth in biopharma engineering, a robust industry presence, and a varied business strategy. The IPO is valued higher than average, and performance may be impacted by execution risks in large-scale projects. As for listing gains, the IPO appears to have received healthy demand and market sentiment. High-risk appetite and confidence in the long-term growth can apply to this IPO with long-term prospects.
The positive GMP and attractive financial performance make this IPO a good choice for investors for long-term listing gains. Cautious Investors may choose to apply for this IPO for short-term listing gains after evaluating the Grey Market Premium trends (GMP) and market sentiment and demand.
Please note:
Investors are advised to make their own decisions and apply entirely at risk. This article uses information from the company’s RHP (Red Herring Prospectus) data and online sources. If you have any queries, kindly contact the IPO Watch Team.
